Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
Open Access
- 1 February 1995
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 181 (2) , 619-629
- https://doi.org/10.1084/jem.181.2.619
Abstract
Mice carrying large established major histocompatibility complex (MHC) class 1+ sarcoma tumors can be successfully treated by immunization with genetically engineered sarcoma cells transfected with syngeneic MHC class II plus B7-1 genes. This approach is significantly more effective than previously described strategies using cytokine- or B7-transduced tumor cells which are only effective against smaller tumor loads, and which cannot mediate regression of longer-term established tumors. The most efficient tumor rejection occurs if both the class II and B7-1 molecules are coexpressed on the same tumor cell. Immunity induced by immunization with class II+B7-1(+)-transfected sarcoma cells involves CD4+ and CD8+ T cells, suggesting that the increased effectiveness of the transfectants is due to their ability to activate both of these T cell populations.Keywords
This publication has 28 references indexed in Scilit:
- Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.The Journal of Immunology, 1994
- MHC Class II-Transfected Tumor Cells Induce Long-Term Tumor-Specific Immunity in Autologous MiceCellular Immunology, 1994
- Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.The Journal of Immunology, 1994
- Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.The Journal of Experimental Medicine, 1994
- Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.1994
- Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.1993
- Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.The Journal of Immunology, 1993
- Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.Proceedings of the National Academy of Sciences, 1993
- IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement.The Journal of Immunology, 1980
- Properties of Monoclonal Antibodies to Mouse Ig Allotypes, H-2, and Ia AntigensPublished by Springer Nature ,1979